Back to Agenda
Session 8, Track 3: Lessons Learned from the FDA GenAI Community Challenge
Session Chair(s)
Kevin Tompkins, MBA
Executive Director, Regulatory Information & Submission Management, Bristol Myers Squibb, United States
The FDA issued a GenAI challenge for the public to demystify the use of GenAI to promote innovation and enhance processes within the FDA. This session will share lessons learned from industry and the FDA who participated in this challenge using both commercial off-the-shelf and custom LLM solutions. The session will focus on highlighting experiences with different technologies and methodologies as LLM technology continues to evolve quickly and it’s impact on industry.
The Precision FDA GenAI Challenge
Samir Lababidi, FDA
FDA GenAI Community Challenge: Low Code Participation
James Averback, Life Sciences Integration Partners
FDA GenAI Community Challenge Pro Code Tier: Lessons Learned
Venkatraman Balasubramanian (Bala), VB Insights, LLC
Learning Objective :
At the conclusion of this session, participants should be able to:
- Describe the impact that LLM solutions are having on our industry
- Evaluate the difference between off-the shelf and custom solutions
- See where the evolution of LLM technology continues to grow
Speaker(s)
The Precision FDA GenAI Challenge
Statistician, FDA, United States
FDA GenAI Community Challenge: Low Code Participation
President, Life Science Integration Partners, United States
FDA GenAI Community Challenge Pro Code Tier: Lessons Learned
Healthcare and Life Sciences Strategic Advisor, VB Insights, LLC, United States
Have an account?